Some synthesized derivatives of berberine (7) with improved efficacy and bioavailability (NAX053, NAX056, NAX057, NAX080 and NAX081) have been reported to increase LC3 lipidation (LC3-II) and consequently are able to stimulate autophagy in human colon carcinoma (HCT116) cells, expressing WT TP53 and in TP53-mutated drug-resistant (SW613-B3) cell lines [149]. Here, TP53 is linked to colon carcinoma.